KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 108 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 4.94 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $23,312,795 | +27.3% | 2,420,851 | +19.0% | 1.26% | +28.7% |
| Q2 2023 | $18,310,554 | +17.5% | 2,034,506 | +2.6% | 0.98% | +48.8% |
| Q1 2023 | $15,587,787 | +115.0% | 1,983,179 | +84.9% | 0.66% | +116.4% |
| Q4 2022 | $7,248,762 | -70.7% | 1,072,302 | -37.2% | 0.30% | -70.5% |
| Q3 2022 | $24,770,000 | +30.6% | 1,707,100 | -11.5% | 1.03% | +42.7% |
| Q2 2022 | $18,973,000 | -26.3% | 1,928,200 | +10.4% | 0.72% | -8.3% |
| Q1 2022 | $25,740,000 | +11.4% | 1,746,300 | 0.0% | 0.79% | +75.8% |
| Q4 2021 | $23,104,000 | -14.2% | 1,746,300 | +13.2% | 0.45% | -1.5% |
| Q3 2021 | $26,930,000 | -5.6% | 1,543,284 | +29.6% | 0.45% | +6.3% |
| Q2 2021 | $28,539,000 | +15.7% | 1,191,101 | +24.1% | 0.43% | +17.0% |
| Q1 2021 | $24,660,000 | +320.4% | 959,892 | +210.7% | 0.36% | +334.5% |
| Q4 2020 | $5,866,000 | +50.8% | 308,900 | 0.0% | 0.08% | +20.0% |
| Q3 2020 | $3,889,000 | +30.1% | 308,900 | +25.1% | 0.07% | +9.4% |
| Q2 2020 | $2,989,000 | +242.0% | 247,000 | +116.3% | 0.06% | +166.7% |
| Q1 2020 | $874,000 | – | 114,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |